This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Non-interventional-study With Tacrolimus Sandoz© Capsules for Prophylaxis of Renal Graft Rejection

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Sandoz
ClinicalTrials.gov Identifier:
NCT01353417
First received: May 12, 2011
Last updated: April 5, 2017
Last verified: April 2017
  Purpose
This non-interventional study intends to collect epidemiological data in patients with stable kidney function after renal transplantation, who receive Tacrolimus Sandoz© according to the approved indication.

Condition Intervention
Chronic Kidney Insufficiency Other: In this observational study no study specific intervention is planned

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: A Single-site, Prospective Non-interventional-study With Adport Sandoz© Capsules for Prophylaxis of Graft Rejection in Patients With Stable Kidney Function After Renal Allograft.

Resource links provided by NLM:


Further study details as provided by Sandoz:

Primary Outcome Measures:
  • Changes in Adport Sandoz© trough level [ Time Frame: Observation time: 26 weeks ]

Secondary Outcome Measures:
  • Efficacy of Adport Sandoz© in prevention of renal graft rejection by observing serum creatinine levels [ Time Frame: Observation time: 26 weeks ]
  • Incidence of serious adverse drug reactions [ Time Frame: Observation time: 26 weeks ]
  • Incidence of adverse drug reactions [ Time Frame: Observation time: 26 weeks ]
  • Incidence of serious adverse events [ Time Frame: Observation time: 26weeks ]

Biospecimen Retention:   Samples Without DNA
Retained types of biospecimen: whole blood, serum, urine

Enrollment: 102
Study Start Date: April 2011
Study Completion Date: August 31, 2015
Primary Completion Date: August 31, 2015 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Renal allograft Other: In this observational study no study specific intervention is planned
Patients with stable kidney function who already receive Tacrolimus Sandoz© capsules before being included in this non-interventional study, are being observed for 6 months by their attending physicians. Routine medical treatment is provided.

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients after renal transplantation who are treated in the general hospital of Vienna on an outpatient basis
Criteria

Inclusion Criteria:

  • Age: ≥ 18
  • Post renal transplantation time: ≥ 6 months
  • Stable kidney function ( serum creatinine < 3.0mg/dl; variation < 0.5mg/dl at 2 appointments in minimum distance of 6 days)
  • Stable Tacrolimus Sandoz© dose > 2 weeks before inclusion in this Non Interventional Study (NIS)
  • Written and oral informed consent

Exclusion Criteria:

  • Well-known poor compliance with immunosuppressives
  • Acute rejection reaction within the past 3 months or antibody-therapy because of rejection within the past 6 months
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01353417

Locations
Austria
General Hospital
Vienna, Austria, 1090
Sponsors and Collaborators
Sandoz
  More Information

Responsible Party: Sandoz
ClinicalTrials.gov Identifier: NCT01353417     History of Changes
Other Study ID Numbers: TAC SAN NIS 2011
Study First Received: May 12, 2011
Last Updated: April 5, 2017

Keywords provided by Sandoz:
Grafting, kidney
Transplantation, kidney

Additional relevant MeSH terms:
Renal Insufficiency
Renal Insufficiency, Chronic
Kidney Diseases
Urologic Diseases
Tacrolimus
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Calcineurin Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on August 18, 2017